AstraZeneca presses camizestrant case with updated SERENA-6 data

AstraZeneca is using ASCO 2026 to keep momentum behind camizestrant after a rocky U.S. regulatory spring. The company highlighted updated Phase III SERENA-6 findings in hormone receptor-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations, including final progression-free survival and new circulating tumor DNA clearance analyses tied to longer-term outcomes. Those new data arrive just weeks after the FDA’s Oncologic Drugs Advisory Committee met on April 30, 2026 to debate the application. (sec.gov)

SERENA-6 first drew attention at the 2025 ASCO Annual Meeting, where investigators reported that patients whose tumors developed an ESR1 mutation on ctDNA testing, but had not yet shown radiographic progression, did better if they switched endocrine backbone therapy from an aromatase inhibitor to camizestrant while continuing their CDK4/6 inhibitor. The study enrolled 3,256 patients for serial ctDNA monitoring, and 315 patients with emergent ESR1 mutations were randomized. ASCO’s press materials described the initial readout as a 56% reduction in the risk of progression or death, with median progression-free survival of 16.0 months versus 9.2 months. Those results were published simultaneously in The New England Journal of Medicine. (asco.org)

The updated picture is more mature, and it’s also more complicated. In FDA briefing documents prepared for the April 2026 ODAC meeting, the agency summarized longer follow-up from the January 2, 2026 data cutoff, showing median progression-free survival of 16.8 months in the camizestrant arm and 9.2 months in the control arm, with a hazard ratio of 0.45. The same FDA materials also underscored several concerns that have shaped the U.S. debate: only 9% of screened patients moved into the randomized portion of the study, U.S. patients accounted for just 14% of the randomized population, and the trial may not fully reflect the current U.S. first-line standard because ribociclib use has increased. (fda.gov)

That regulatory context matters because the April 30, 2026 ODAC discussion did not go AstraZeneca’s way. Multiple reports on the meeting said the committee voted 6-3 against finding a favorable benefit-risk profile for camizestrant plus a CDK4/6 inhibitor in this setting, with concerns centered on trial design, clinical meaningfulness, and the absence of mature overall survival data. AstraZeneca later disclosed that the FDA extended the PDUFA date to review additional analyses, including the ctDNA clearance results being presented at ASCO 2026. The company also said the European Medicines Agency’s CHMP adopted a positive opinion on May 22, 2026, creating a notable U.S.-EU split in regulatory posture. (targetedonc.com)

Industry and expert reaction has reflected that split between enthusiasm for the biology and caution about the evidence threshold. Ahead of the initial 2025 presentation, ASCO expert Eleonora Teplinsky, MD, called SERENA-6 a potential new first-line treatment paradigm because it tested an early switch strategy based on molecular progression rather than waiting for overt clinical progression. At the same time, commentary in npj Breast Cancer this year argued that SERENA-6 is important proof of concept for ctDNA-guided care, while also raising unresolved questions around assay thresholds, spontaneous fluctuation or clearance of ESR1 mutations, and how best to define a clinically actionable molecular progression event. (asco.org)

Why it matters: For oncology practices, SERENA-6 is bigger than a single drug. It’s a test of whether routine serial liquid biopsy should become part of first-line management for some patients with metastatic HR-positive disease, and whether a biomarker-triggered switch can prolong time on endocrine-based therapy before radiographic progression. If that model holds up, it could reshape monitoring workflows, testing cadence, treatment sequencing, and payer discussions. But the FDA’s pushback is a reminder that a statistically strong progression-free survival result doesn’t automatically settle questions about real-world clinical benefit, generalizability, or how much evidence is needed to justify treatment changes before conventional progression. (fda.gov)

The competitive landscape is also moving. On May 1, 2026, the FDA approved vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy, showing that ESR1-targeted endocrine therapy is already gaining ground, though in a later-line setting than SERENA-6 is trying to define. That makes AstraZeneca’s effort especially consequential: the company isn’t just arguing that camizestrant works, but that earlier intervention based on ctDNA can create a new treatment window. (fda.gov)

What to watch: The near-term question is whether the new ctDNA clearance analyses presented at ASCO on June 2, 2026 can address FDA concerns well enough to support approval after the extended review, and the longer-term question is whether clinicians embrace ctDNA-triggered switching as a new standard or wait for more mature survival and implementation data. (sec.gov)